Bcl2L13 is a ceramide synthase inhibitor in glioblastoma

Therapy resistance is a major limitation to the successful treatment of cancer. Here, we identify Bcl2-like 13 (Bcl2L13), an atypical member of the Bcl-2 family, as a therapy susceptibility gene with elevated expression in solid and blood cancers, including glioblastoma (GBM). We demonstrate that mi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Jensen, Samuel A., Calvert, Andrea E., Volpert, Giora, Kouri, Fotini M., Hurley, Lisa A., Luciano, Janina P., Wu, Yongfei, Chalastanis, Alexandra, Futerman, Anthony H., Stegh, Alexander H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2014
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3992626/
https://ncbi.nlm.nih.gov/pubmed/24706805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1316700111
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller